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Busan and Yangsan, South KoreaObjectives The aim of this study was to systematically review and perform a meta-analysis of
randomized trials and observational studies of intravascular ultrasound (IVUS)-guided versus
angiography-guided implantation of drug-eluting stents (DES).
Background Although studies in the bare-metal stents era suggested that there were clinical beneﬁts
to IVUS guidance, it is still controversial whether percutaneous coronary intervention (PCI) with DES
guided by IVUS leads to better clinical outcomes.
Methods Relevant studies published through March 31, 2013, were searched for and identiﬁed in the
electronic databases. Summary estimates were obtained using a random-effects model.
Results From 138 initial citations, 3 randomized trials and 12 observational studies with 24,849
patients (11,793 IVUS-guided and 13,056 angiography-guided) were included in this study.
Comparison of IVUS- versus angiography-guided PCI disclosed odds ratios (ORs) for major adverse
cardiac events of 0.79 (95% conﬁdence interval [CI]: 0.69 to 0.91; p ¼ 0.001). IVUS-guided PCI was also
associated with signiﬁcantly lower rates of all-cause mortality (OR: 0.64; 95% CI: 0.51 to 0.81; p < 0.001),
myocardial infarction (OR: 0.57; 95% CI: 0.42 to 0.78; p < 0.001), target vessel revascularization (OR:
0.81; 95% CI: 0.68 to 0.95; p ¼ 0.01), and stent thrombosis (OR: 0.59; 95% CI: 0.42 to 0.82; p ¼ 0.002).
A meta-analysis of propensity-matched studies demonstrated similar results in terms of clinical
outcomes, but not repeat revascularization.
Conclusions IVUS-guided DES implantation is associated with signiﬁcantly lower rates of adverse
clinical events compared with angiography guidance. Further study is needed to clarify which
subgroups of subjects with IVUS guidance will have greater beneﬁt. (J Am Coll Cardiol Intv 2014;
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234Intravascular ultrasound (IVUS) plays a substantial role
in percutaneous coronary intervention (PCI) using coro-
nary stents not only by providing more accurate informa-
tion about the coronary artery and implanted stents but
also by allowing earlier detection of procedure-related
complications and suboptimal stent expansion. Previous
studies and meta-analyses have demonstrated that IVUS-
guided stent implantation may decrease restenosis and the
adverse clinical outcomes after bare-metal stent (BMS)
implantation (1–3).
It is still controversial whether implantation of drug-
eluting stents (DES) guided by IVUS could reduce adverse
clinical outcomes. Zhang et al. (4) recently performed a meta-
analysis on this topic. They included 1 randomized trial and
10 observational studies comparing IVUS- and angiography-
guided DES implantation in the DES era. However, they
included a study (5) in which some of the patients receivedAbbreviations
and Acronyms
BMS = bare-metal stent(s)
CI = conﬁdence interval
DES = drug-eluting stent(s)
HR = hazard ratio
IVUS = intravascular
ultrasound
MACE = major adverse
cardiac events
MI = myocardial infarction
OR = odds ratio
PCI = percutaneous coronary
intervention
TLR = target lesion
revascularization
TVR = target vessel
revascularizationBMS. There has been the recent
presentation (6) and publication
of additional randomized trials
(7,8) and an observational study
(9) comparing IVUS and angio-
graphic-guided DES implanta-
tion. This suggests the need for an
updated meta-analysis to further
support the efﬁcacy of IVUS-
guided DES implantation.Methods
Data sources and searches. We
identiﬁed relevant studies through
electronic searches ofMEDLINE,
EMBASE, and the Cochrane
Central Register of Controlled
Trials from January 2001 throughMarch 2013. Medical subject headings and keyword searches
included intravascular ultrasound, coronary angiography, stents,
drug-eluting stents, coronary angioplasty, and percutaneous
coronary intervention. Reference lists of selected articles were
reviewed for other potentially relevant citations. In addition, we
manually searched the content pages of issues published from
2011 through 2012 by theAmericanCollege of Cardiology, the
European Society of Cardiology, the Transcatheter Cardio-
vascular Therapeutics, and the American Heart Association to
retrieve further potential publications.
Study selection. Two investigators (J.-S.J. and H.-Y.J.)
independently conducted the literature search, data extrac-
tion, and quality assessment by using a standardized
approach. Selected publications were reviewed by the same
investigators to assess whether studies met the inclusion
criteria: comparison of IVUS- and angiography-guided PCI
with DES implantation in which follow-up angiographicand/or clinical outcome data were reported. Final inclusion
of studies was based on the agreement of both reviewers.
Data extraction and quality assessment. Two reviewers
(J.-S.J. and T.-H.Y.) extracted relevant information from
the papers including study design, follow-up duration, pa-
tient characteristics (mean age, sex distribution, risk factors),
and angiographic/procedural characteristics. To reduce the
effect of treatment-selection bias and potential confounding
in nonrandomized observational studies, we also abstracted
adjusted risk estimates from observational studies. If addi-
tional information was needed, the authors of the studies
were contacted.
Endpoints. The endpoints of this study were major adverse
cardiac events (MACE), all-cause mortality, myocardial
infarction (MI), target vessel revascularization (TVR), target
lesion revascularization (TLR), stent thrombosis, and post-
intervention minimal lumen diameter. The deﬁnition of
MACE was slightly different across studies, and we used the
trial-speciﬁc deﬁnitions of MACE. Most of the included
studies deﬁned MACE as a composite of all-cause death,
MI, and TVR. Four studies (7,8,10,11) included cardio-
vascular death instead of all-cause death, and the other 2
studies (12,13) included TLR instead of TVR. MI included
Q-wave MI and non–Q-wave MI. Stent thrombosis was
deﬁnite or probable according to the deﬁnition of the
Academic Research Consortium (14).
Data synthesis and analysis. We used random-effects
models to produce across-study summary odds ratios (ORs)
with 95% conﬁdence intervals (CIs). A crude OR with 95%
CI was used to assess the efﬁcacy of IVUS guidance on
adverse clinical events in study populations. Continuous data
were expressed as mean (SD) and weighted mean differ-
ences. All p values were 2 tailed, with statistical signiﬁcance
set at 0.05. For comparison of registry studies with matched
pairs by propensity score analysis, adjusted risk estimates
were pooled after logarithmic transformation according
to random-effects models with generic inverse variance
method.
We assessed statistical heterogeneity between trials with
the I2 statistic, which is derived from Cochran’s Q and the
degree of freedom [100  (Q–df)/Q)] (15). I2 values
>25%, 50%, and 75% were considered evidence of low,
moderate, and severe statistical heterogeneity, respectively.
In case of heterogeneity across the studies, we performed
sensitivity analyses, serially excluding studies to determine
the source of heterogeneity. Additionally, sensitivity analyses
were conducted to examine the heterogeneity on the basis of
coronary anatomy (bifurcation vs. nonbifurcation and left
main vs. non–left main), the study design (randomized
vs. nonrandomized studies), and the publication period
(previous vs. new studies). Publication bias was examined by
visual inspection of constructed funnel plots for clinical
outcomes and mathematically by means of the Egger test
(p for signiﬁcant asymmetry <0.1) (16). All statistical
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235analyses were performed using Review Manager version 5.1
(The Nordic Cochrane Center, Copenhagen, Denmark) and
MIX version 2.0 (BiostatXL, Sunnyvale, California).
This meta-analysis was performed according to the
PRISMA (Preferred Reporting Items for Systematic reviews
and Meta-Analysis) statements (17).Results
A total of 138 publications were reviewed, and 35 studies
were selected for inclusion and further evaluated. Three
studies were excluded because DES data could not be
extracted from the database (5,18,19). Subsequently, 15
clinical studies were included in the ﬁnal analysis (Fig. 1)
(6–13,20–26). Characteristics of the included studies are
summarized in Table 1. Of the 24,849 patients, 11,793
patients underwent IVUS-guided PCI and 13,056 under-
went angiography-guided PCI.
The HOME DES IVUS (Long-Term Health Outcome
and Mortality Evaluation After Invasive Coronary Treat-
ment Using Drug Eluting Stents with or without the IVUS
Guidance) study (12), the AVIO (Angiography Vs. IVUS
Optimization) trial (7), and the RESET (Real Safety and
Efﬁcacy of a 3-Month Dual Antiplatelet Therapy Following
Zotarolimus-Eluting Stents Implantation) trial (8) wereFigure 1. Trial Flowchart
The chart shows the number of studies retrieved by individual searches and
number of trials included in the review.prospective, randomized trials that assessed the routine use
of IVUS guidance during DES deployment. The other 12
studies were observational cohort studies with matched co-
horts or consecutive patients (6,9–11,13,20–26). To identify
possible differences between groups, prevalence of risk factors
(diabetes, hypertension, hyperlipidemia, current smoking,
history of PCI or MI), American College of Cardiology/
American Heart Association B2/C lesion, left ventricular
ejection fraction, and proportion of patients with acute cor-
onary syndrome were extracted and compared (Table 1).
Of the 15 studies, 3 studies (21,23,25) had routine angio-
graphic follow-up data available at 6 or 12 months, and
2 studies (7,25) reported rates of restenosis. Four recent
studies included zotarolimus- (24) or everolimus-eluting
stents (8,9,24,25), whereas most earlier studies used siroli-
mus- and paclitaxel-eluting stents (10,12,13,20–23,26).
Three studies (6,7,11) did not report the type of DES used.
Angiographic and procedural characteristics are shown in
Table 2. Quantitative coronary angiography results of
included studies were compared in detail between IVUS- and
angiography-guided PCI groups (Online Table 1).
Major adverse cardiac events. Eleven studies reported the
incidence of MACE at follow-up. The summary OR was
0.79 (95% CI: 0.69 to 0.91; p ¼ 0.001) (Fig. 2) in favor of
IVUS-guided PCI. No evidence of statistical heterogeneity
was noted among the included studies (heterogeneity chi-
square ¼ 11.13, I2 ¼10%, p ¼ 0.35).
Stratiﬁed analysis by the study design demonstrated a
signiﬁcantly lower incidence of MACE with IVUS-guided
PCI in nonrandomized studies (OR: 0.81; 95% CI: 0.68 to
0.96; p ¼ 0.02) compared with randomized trials that failed
to show signiﬁcant beneﬁt of IVUS- over angiography-
guided PCI (OR: 0.69; 95% CI: 0.46 to 1.04; p ¼ 0.07)
(7,8,12). Sensitivity analyses were performed for MACE
according to coronary anatomy. Performing a meta-analysis
after exclusion of studies with predominantly bifurcation
lesion did not offset the beneﬁt of IVUS guidance (OR:
0.78; 95% CI: 0.65 to 0.94; p ¼ 0.009) (11,13). Also,
sensitivity analysis of left main coronary disease did not
change the overall results favoring IVUS-guided PCI over
angiography-guided PCI (OR: 0.80; 95% CI: 0.69 to 0.92;
p ¼ 0.002) (20).
All-cause mortality, MI, TVR, and TLR. IVUS-guided PCI was
associated with signiﬁcantly lower rates of all-cause mortality
(OR: 0.64; 95% CI: 0.51 to 0.81; p< 0.001), MI (OR: 0.57;
95% CI: 0.42 to 0.78; p < 0.001), and TVR (OR: 0.81; 95%
CI: 0.68 to 0.95; p ¼ 0.01) (Fig. 3). Evidence of statistical
heterogeneity was noted among studies with all-cause mor-
tality (heterogeneity chi-square¼ 18.67, I2¼ 36%, p¼ 0.10),
MI (heterogeneity chi-square ¼ 17.32, I2 ¼ 37%, p ¼ 0.10),
and TVR (heterogeneity chi-square ¼ 16.23, I2 ¼ 38%,
p ¼ 0.09).
Of the 15 studies, 7 were included for the analysis of TLR
(7,9,11–13,21,25). The risk of TLR was signiﬁcantly lower
Table 1. Characteristics of Included Studies and Patients
First Author/Study
(Ref. #), Year Design
Sample
Size
Angiographic
Follow-Up,
months
Clinical
Follow-Up,
months
Age,
yrs Male, %
Diabetes
Mellitus, % Hypertension, % Dyslipidemia, % Smoker, %
Previous
PCI, %
Previous
MI, % ACS, %
ACC/AHA
B2C Lesions LVEF, %
Agostoni et al. (20), 2005 Observational 24/34 NA 14 62/64 62/73 37/29 58/59 62/68 17/21 50/21 37/50 33/32 NA 52/44
Roy et al. (21), 2008 Observational 884/884 12 12 66/65 69/70 35/34 81/81 86/87 21/20 27/24 43/41 62/60 95/95 47/48
MAIN-COMPARE (22), 2009 Observational 145/145 NA 36 64/65 70/70 34/34 59/59 29/30 19/21 26/26 7/8 63/61 NA 60/61
Kim et al. (23), 2010 Observational 473/285 12 48 59/60 73/72 20/22 43/46 28/35 36/36 10/7 NA 52/64 NA 60/59
Jakabcim et al. (12), 2010 RCT 105/105 NA 18 59/60 73/71 42/45 67/71 63/66 40/35 17/14 37/32 72/60 100/100 NA
MATRIX (10), 2011 Observational 548/548 NA 24 64/64 73/73 31/31 81/80 83/82 11/10 43/42 29/34 32/35 67/62 NA
COBIS (13), 2011 Observational 487/487 NA 36 62/61 66/66 31/33 60/58 34/34 21/22 NA 8/8 53/56 NA 60/58
Youn et al. (24), 2011 Observational 125/216 NA 36 60/61 74/63 27/32 50/51 22/11 75/57 10/5 9/6 NA 81/75 (type C) 45/48
ADAPT-DES (6), 2012 Observational 3,349/5,234 NA 12 63/64 73/75 31/33 78/81 68/78 25/21 NA 25/26 13/8 NA NA
Chen et al. (11), 2013 Observational 324/304 NA 12 63/65 81/75 19/18 67/61 33/35 45/41 18/17 15/12 87/80 NA 61/60
EXCELLENT (25), 2013 Observational 463/463 9 12 62/62 65/63 37/37 72/74 76/77 52/50 NA 3/3 50/51 58/53 NA
Hur et al. (26), 2013 Observational 4,627/3,744 NA 36 58/61 71/68 22/25 43/47 28/29 35/35 9/7 NA 53/65 NA 58/57
AVIO (7), 2013 RCT 142/142 Various 24 64/64 83/77 24/27 70/67 70/77 35/31 NA NA 30/26 NA 55/56
RESET (8), 2013 RCT 269/274 NA 12 63/64 66/55 32/30 61/66 61/62 22/17 NA 1/3 47/48 NA 55/54
IRIS-DES (9), 2013 Observational 1,616/1,628 NA 24 62/64 69/64 31/32 57/63 40/34 30/29 NA 1/2 51/69 NA 60/59
Values are presented as intravascular ultrasound/no intravascular ultrasound.
ACC/AHA ¼ American College of Cardiology/American Heart Association; ACS ¼ acute coronary syndrome; ADAPT-DES ¼ Assessment of Dual AntiPlatelet Therapy with Drug-Eluting Stents; AVIO ¼ Angiography Vs. IVUS Optimization; EXCELLENT ¼ Efﬁcacy of
Xience/Promus versus Cypher in Reducing Late Loss after Stenting; IRIS-DES ¼ Interventional Cardiology Research In-cooperation Society-Drug-Eluting Stents; LVEF ¼ left ventricular ejection fraction; MAIN-COMPARE ¼ revascularization for unprotected left MAIN
coronary artery stenosis: COMparison of Percutaneous coronary Angioplasty versus surgical REvascularization; MATRIX ¼ Comprehensive Assessment of Sirolimus-Eluting Stents in Complex Lesions; MI ¼ myocardial infarction; NA ¼ not applicable; PCI ¼
percutaneous coronary intervention; RCT ¼ randomized, controlled trial; RESET ¼ Real Safety and Efﬁcacy of a 3-Month Dual Antiplatelet Therapy Following Zotarolimus-Eluting Stents Implantation.
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Table 2. Angiographic and Procedural Characteristics
First Author/Study
(Ref. #)
LAD
Involved,
%
LCX
Involved,
%
RCA
Involved,
%
Left Main
Involved,
%
Multivessel
PCI,
%
Direct
Stenting
Pre-
Dilation
Post-
Dilation
Maximal
Balloon
Pressure,
atm
Maximal
Balloon Size,
mm
Lesion
Length,
mm
IABP
Use, %
Gp IIb/
IIIa
Inhibitor
Use, %
Bifurcation
Stenting,
%
Final
Kissing,
%
CTO,
%
Ostial
Lesion,
%
Agostoni et al. (20) NA NA 12/26 100/100 54/59 NA 50/62 92/76 17.8/17.8 NA 7.47  3.05/7.33  3.11 4/15 46/23 70/50 40/45 NA 29/9
Roy et al. (21) 32/33 24/23 34/34 2.0/2.3 NA 28/41 NA 31/17 NA NA NA 2/3 17/18 NA NA NA 3/3
MAIN-COMPARE (22) NA NA 52/55 100/100 NA 21/16 NA NA NA NA NA 4/2 6/4 38/38 NA NA NA
Kim et al. (23) NA NA NA NA 29/34 NA NA NA NA 3.6  0.4/3.4  0.5 25  14/21  10 NA 4/3 NA NA 3/3 13/3
HOME DES IVUS (12) 56/54 11/15 29/24 3/4 15/17 26/23 NA NA 16.4  0.7/15.2  1.5 3.3  0.4/3.1  0.4 18.1  7.3/17.6  6.7 NA 20/16 NA NA NA NA
MATRIX (10) 51/50 37/38 28/28 3/3 NA NA 54/70 42/34 15.5  2.6/15.3  2.6 NA 17.5  9.6/17.9  9.3 NA 8/8 NA NA NA 8/7
COBIS (13) 83/82 12/12 4/4 3/3 46/47 NA 100/100
(MV)
22/21 (SB)
NA NA NA 17.6  10.8/19.0  11.4 (MV)
5.5  6.2/5.1  6.1 (SB)
NA 3/3 27/16 53/33 6/7 (MV)
3/3 (SB)
NA
Youn et al. (24) 60/46 5/9 33/42 1/1 18/18 NA NA 54/33 NA NA NA NA 16/3 NA NA NA NA
ADAPT-DES (6) NA NA NA NA NA NA NA NA 16.9  3.7/16.7  3.5 3.44  0.56/3.15  0.50 NA NA NA NA NA NA NA
Chen et al. (11) 40/61 14/9 4/3 42/27 NA NA 48/52 (MV)
51/60 (SB)
NA 13.3  1.3/11.8  1.7 NA 24.83  12.75/23.98  11.25 NA 3/7 100/99 95/93 5/4 5/10
EXCELLENT (25) 54/50 20/24 27/27 NA NA NA NA NA NA NA 21.5  12.8/20.1  11.1 NA NA NA NA NA NA
Hur et al. (26) 59/50 12/22 25/34 8/3 28/33 10/5 NA NA 14.1  4.2/12.8  3.8 3.6  0.6/3.3  0.6 NA NA NA NA NA 4/4 11/5
AVIO (7) 53/49 NA NA NA NA NA NA NA 20.3  4.82/19.6  4.0 3.39  0.47/3.15  0.40 27.4  15.9/25.5  15.0 NA NA 23/27 NA 14/18 NA
RESET (8) 62/68 15/13 23/20 0/0 NA NA NA 55/45 13.5  3.3/13.5  3.1 3.1  0.4/3.1  0.4 29.6 (23.2–42.8)/30.6 (24.2–40.9) NA NA NA 1/2 0/0 0/0
IRIS-DES (9) 63/59 NA NA 9/2 NA NA NA NA NA NA NA NA NA NA NA 10/16 NA
Values are %, n, mean  SD, or odds ratio (95% conﬁdence interval), and are presented as intravascular ultrasound/no intravascular ultrasound.
CTO ¼ chronic total occlusion; Gp ¼ glycoprotein; IABP ¼ intra-aortic balloon pump; LAD ¼ left anterior descending artery; LCX ¼ left circumﬂex artery; MV ¼ main vessel; RCA ¼ right coronary artery; SB ¼ side branch; other abbreviations as in Table 1.
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Figure 2. ORs for MACE With IVUS- Versus Angiography-Guided PCI Stratiﬁed by Study Design
The incidence of major adverse cardiac events (MACE) was lower in the intravascular ultrasound (IVUS)-guided percutaneous coronary intervention (PCI) group.
Randomized trials failed to show a signiﬁcant beneﬁt of IVUS-guided PCI. CI ¼ conﬁdence interval; DES ¼ drug-eluting stent; OR ¼ odds ratio; M-H ¼ Mantel-Haenszel.
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238in patients with IVUS guidance (OR: 0.76; 95% CI: 0.62 to
0.94; p ¼ 0.01). There was no statistically signiﬁcant evi-
dence of heterogeneity (heterogeneity chi-square ¼ 2.06,
I2 ¼ 0%, p ¼ 0.91).
Stent thrombosis. Data on stent thrombosis was reported in
14 studies. IVUS-guided PCI was associated with a signif-
icantly lower rate of deﬁnite or probable stent thrombosis
compared with patients treated without IVUS guidance
(OR: 0.59; 95% CI: 0.42 to 0.82; p ¼ 0.002) (Fig. 4).
Statistical heterogeneity was noted among the included
studies (heterogeneity chi-square ¼ 17.52, I2 ¼ 26%, p ¼
0.18). None of the studies inﬂuenced the results to an extent
that the conclusion would have changed: the sensitivity
analysis of the stent thrombosis risk with IVUS-guided PCI
after exclusion of 1 study at a time yielded effect sizes similar
in magnitude and direction to the overall estimates.
Post-intervention minimal lumen diameter. Nine studies
including 4,703 patients were applied to the analysis of post-
intervention minimal lumen diameter. The mean post-
intervention minimal lumen diameter ranged from 2.50 to
3.00 mm in the IVUS-guided PCI group and from 2.40 to
2.87 mm in the angiography-guided PCI group. The pooled
weighted mean difference of post-intervention minimal
lumen diameter was 0.12 mm (95% CI: 0.08 to 0.16 mm;p < 0.001) (Fig. 5). Statistical heterogeneity was noted
among the included studies (heterogeneity chi-square ¼
20.22, I2 ¼ 60%, p ¼ 0.01).
Propensity score–matched pairs analysis. Propensity score–
matched adjusted estimates for IVUS- versus angiography-
guided PCI could be analyzed in 9 studies (Online Fig. 1)
(9–11,13,21–23,25,26). Adjusted risk estimates for MACE
(hazard ratio [HR]: 0.79; 95%CI: 0.66 to 0.95; p¼ 0.01), all-
cause death (HR: 0.58; 95% CI: 0.42 to 0.81; p¼ 0.001), MI
(HR: 0.56; 95% CI: 0.33 to 0.97; p ¼ 0.04), and stent
thrombosis (HR: 0.52; 95%CI: 0.34 to 0.82; p¼ 0.004) were
signiﬁcantly lower in the IVUS-guided PCI group. However,
no signiﬁcant differences were observed for the risk of TVR
and TLR between the 2 groups (HR: 0.93; 95% CI: 0.79 to
1.09; p¼ 0.34 andHR: 0.85; 95%CI: 0.64 to 1.13; p¼ 0.26).
Statistical heterogeneity was noted among studies reporting
MACE, all-cause death, MI, and stent thrombosis.
Publication bias. Assessment of publication bias using the
ORs of clinical outcomes of the included studies demon-
strated a symmetrical funnel plot with no evidence of
publication bias for the primary analysis by the Egger
regression-based test (p ¼ 0.55 for MACE, p ¼ 0.86 for
all-cause death, p ¼ 0.76 for MI, p ¼ 0.39 for TVR, p ¼
0.31 for TLR, and p ¼ 0.73 for stent thrombosis) (Fig. 6).
Figure 3. ORs for All-Cause Death, MI, and TVR With IVUS- Versus Angiography-Guided PCI
IVUS-guided PCI was associated with lower odds of all-cause death, myocardial infarction (MI), or target vessel revascularization (TVR). Abbreviations as
in Figure 2.
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Figure 4. ORs for Stent Thrombosis With IVUS- Versus Angiography-Guided PCI Stratiﬁed by Study Design
The incidence of stent thrombosis was lower among patients with IVUS-guided PCI. Randomized trials failed to show signiﬁcant beneﬁt of IVUS-guided PCI.
Abbreviations as in Figure 2.
Jang et al. J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 7 , N O . 3 , 2 0 1 4
IVUS-Guided Coronary Intervention M A R C H 2 0 1 4 : 2 3 3 – 4 3
240Discussion
In the present meta-analysis of 3 randomized trials and 12
observational studies consisting of 24,849 patients, we found
that IVUS-guided DES implantation is associated with a
21% reduction in the risk of MACE and a 36% reduction inFigure 5. Mean Difference of Post-Intervention Minimal Lumen Diameter With IV
The pooled weighted mean difference of post-intervention minimal lumen diameterthe risk of mortality compared with angiography-guided
PCI. This is in agreement with the previous meta-analysis of
11 studies including 19,619 patients with PCI (4), which
demonstrated a 41% reduction in mortality with IVUS
guidance. In addition, IVUS-guided PCI reduced MI,
TVR, TLR, and stent thrombosis compared withUS-Guided Versus Angiography-Guided PCI
was 0.12 mm in favor of IVUS-guided PCI. Abbreviations as in Figure 2.
Figure 6. Funnel Plots for Assessment of Publication Bias
Assessment of publication bias using ORs of clinical outcomes illustrates symmetrical funnel plots with no evidence of publication bias conﬁrmed by a negative Egger
test. p ¼ 0.55 for MACE (A), p ¼ 0.86 for all-cause death (B), p ¼ 0.76 for myocardial infarction (MI) (C), p ¼ 0.39 for TVR (D), p ¼ 0.31 for target lesion revascularization
(TLR) (E), and p ¼ 0.73 for stent thrombosis (F). Abbreviations as in Figure 2 and 3.
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241angiography-guided PCI. Analysis of 9 propensity score–
matched studies including 13,545 patients demonstrated
broadly similar results in terms of clinical outcomes, but no
statistically signiﬁcant difference in repeat revascularization.
It is still controversial whether routine IVUS guidance
improves clinical outcomes after PCI with coronary
stents. Although earlier studies demonstrated a signiﬁcant
beneﬁt in reducing repeat revascularization after BMS
implantation (1,2), several other studies have failed to
prove the beneﬁcial effects of IVUS-guided stent im-
plantation (12,27). Among 15 studies included in our
meta-analysis, only the EXCELLENT (Efﬁcacy of
Xience/Promus versus Cypher in Reducing Late Loss
after Stenting) study reported data on binary angiographic
restenosis (25), which were not signiﬁcantly different
between IVUS guidance and angiography guidance (1.7%
vs. 1.1%, p ¼ 0.373). Moreover, they showed an increased
incidence of MACE at 1 year (HR: 2.40; 95% CI: 1.15 to
5.02; p ¼ 0.02), mainly due to an increased risk ofperiprocedural MI with IVUS guidance. According to a
meta-analysis performed in the pre-DES era (3), IVUS
guidance was associated with a larger postprocedure
angiographic minimal lumen diameter with signiﬁcantly
lower rates of angiographic restenosis (OR: 0.64; 95% CI:
0.42 to 0.96; p ¼ 0.02) and repeat revascularization (OR:
0.66; 95% CI: 0.48 to 0.91; p ¼ 0.004). However, the
advantage of IVUS-guided DES implantation seems to be
related to achievement of a lower incidence of MI or risk
of death rather than a decreased rate of angiographic
restenosis or need for repeat revascularization. The
mechanism of beneﬁcial effects of IVUS guidance in the
DES era might be the capability to identify factors asso-
ciated with periprocedural complications, such as side
branch occlusion, stent edge dissections and hematoma,
stent underexpansion, and incomplete stent apposition
(28,29).
Zhang et al. (4) reported in their recent meta-analysis that
IVUS guidance was associated with signiﬁcantly lower rates
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242of mortality (HR: 0.59; 95% CI: 0.48 to 0.73; p < 0.001),
MACE (HR: 0.87; 95% CI: 0.78 to 0.96; p ¼ 0.008),
and stent thrombosis (HR: 0.58; 95% CI: 0.44 to 0.77;
p < 0.001) compared with angiography-guided PCI, but it
did not reduce MI, TLR, or TVR. Recently, the ADAPT-
DES (Assessment of Dual AntiPlatelet Therapy with Drug-
Eluting Stents) study was published (6). Witzenbichler et al.
(6) showed that IVUS guidance during DES PCI was
associated with a signiﬁcantly reduced incidence of stent
thrombosis (0.6% vs. 1.0%, p ¼ 0.02), MI (2.5% vs. 3.7%,
p ¼ 0.002), and ischemia-driven TVR (2.4% vs. 4.0%,
p < 0.001) compared with PCI without IVUS. The results
of the present study correspond with the previous studies.
However, analyses of 3 randomized trials and 12 observation
studies from the present work, including >24,000 patients,
further support the efﬁcacy of IVUS-guided PCI with DES
implantation, with an OR of 0.79 for MACE in favor of
IVUS guidance compared with angiography-guided PCI
without signiﬁcant heterogeneity or evidence of publication
bias. In addition, we extracted DES data exclusively from
the included studies and tried not to include studies mixed
with BMS data.
Our study corresponds to several previous studies pro-
posing a possibility that IVUS-guided PCI may reduce
DES-related stent thrombosis. With IVUS, assessment of
suboptimal results of coronary stenting associated with the
occurrence of stent thrombosis is possible. IVUS evaluations
of stent underexpansion, malapposition, incomplete lesion
coverage, and residual plaque have been found to predict
stent thrombosis after DES implantation (30–33). Also,
selection of appropriate stenting strategy according to the
IVUS ﬁndings might be important in reducing adverse
outcomes. The ﬁnding of reduced deﬁnite or probable stent
thrombosis in the IVUS guidance group of our study is in
keeping with these ﬁndings.
Study limitations. First, most studies included in our meta-
analysis were observational studies from different cohorts
or consecutive patients. Therefore, we abstracted pro-
pensity score–matched adjusted risk estimates from
observational studies with generic inverse variance
weighting. Second, the deﬁnition of endpoints differed
among the included studies. Third, there was wide vari-
ability in risk proﬁle and lesion complexity of the included
patients. In addition, we could not have access to patient-
level data to determine whether speciﬁc lesion subsets (e.g.,
left main and bifurcation lesions) or other risk factors (e.g.,
diabetes and advanced age) would inﬂuence the effect of
IVUS guidance on the adverse clinical outcomes. Fourth,
some results of our meta-analysis have signiﬁcant hetero-
geneity, which is frequent in meta-analyses performed on
global data. Thus, we tried to overcome heterogeneity by
sensitivity analyses of the lesion subsets and according to
study design. Finally, the types of DES used were different
among the included studies.Conclusions
Our meta-analysis demonstrates that IVUS-guided DES
implantation signiﬁcantly reduces adverse clinical outcomes
compared with angiography-guided PCI. These data should
provide further support for IVUS use in the modern DES
era, but adequately powered trials that measure patient-ori-
ented outcomes in participants with different risk proﬁles
and lesion subsets are needed.
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